Cytochrome P-450 CYP2C9 Inhibitors

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2C9.

Also Known As:

CYP2C9 Inhibitors; P450 CYP2C9 Inhibitors; CYP2C9 Inhibitors, P450; Cytochrome P 450 CYP2C9 Inhibitors; Inhibitors, CYP2C9; Inhibitors, P450 CYP2C9

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Cytochrome P-450 Enzyme Inhibitors: 8
        Cytochrome P-450 CYP2C9 Inhibitors: 6
  - Metabolic Side Effects of Drugs and Substances: 5
    - Cytochrome P-450 Enzyme Inhibitors: 8
      - Cytochrome P-450 CYP2C9 Inhibitors: 6

Experts

1.	Aghai, Fatemeh: 1 article (12/2021)
2.	Grigoleit, Götz Ulrich: 1 article (12/2021)
3.	Isberner, Nora: 1 article (12/2021)
4.	Klinker, Hartwig: 1 article (12/2021)
5.	Kraus, Sabrina: 1 article (12/2021)
6.	Kurlbaum, Max: 1 article (12/2021)
7.	Scherf-Clavel, Oliver: 1 article (12/2021)
8.	Zimmermann, Sebastian: 1 article (12/2021)
9.	De Zwart, Loeckie: 1 article (01/2021)
10.	Goris, Ivo: 1 article (01/2021)

Related Diseases

1.	Hemorrhage 01/01/2009 - "Adjusted odds ratio (OR) for bleeding was highest for cytochrome P450 2C9 (CYP2C9) inhibitors (OR 3.6; 95% confidence interval (CI) 2.4-5.6). " 04/01/2017 - "Patients concomitantly treated with warfarin and SSRIs that are potent CYP2C9 inhibitors had comparable rates of bleeding events, ischemic or thromboembolic events, and mortality as did patients cotreated with warfarin and other SSRIs, although small but potentially meaningful effects on bleeding cannot be completely excluded. " 04/01/2017 - "Some SSRIs are potent CYP2C9 inhibitors that may increase warfarin plasma concentrations and the risk of bleeding. " 04/01/2017 - "Cox regression models were used to estimate hazard ratios and 95% confidence intervals for bleeding events, ischemic or thromboembolic events, and mortality comparing patients treated with SSRIs that are potent CYP2C9 inhibitors (fluoxetine, fluvoxamine) with those treated with other SSRIs after propensity score matching. "
2.	Primary Myelofibrosis (Myelosclerosis) 12/01/2021 - "Ruxolitinib exposure is increased in GvHD patients in comparison to myelofibrosis patients due to reduced clearance and comedication with CYP3A4 or CYP2C9 inhibitors. "
3.	Neoplasms (Cancer) 01/01/2021 - "This article describes a physiologically based pharmacokinetic (PBPK) model for erdafitinib to assess the drug-drug interaction (DDI) potential of CYP3A4 and CYP2C9 inhibitors and CYP3A4/CYP2C9 inducers on erdafitinib pharmacokinetics (PK) in patients with cancer exhibiting higher AGP levels and in populations with different CYP2C9 genotypes. "
4.	Myocardial Infarction 07/01/2007 - "Neither the use of CYP2C9 inhibitors or substrates nor the variant CYP2C9 alleles were associated with an increased risk of myocardial infarction in men. "
5.	Liver Diseases (Liver Disease) 12/01/2018 - "Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors."

Related Drugs and Biologics

1.	Cytochrome P-450 CYP3A
2.	Cytochrome P-450 CYP2C9
3.	Cytochrome P-450 CYP2C9 Inducers
4.	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)
5.	Fluvoxamine (Luvox)
6.	Warfarin (Coumadin)
7.	Fluoxetine (Prozac)
8.	Cytochrome P-450 Enzyme System (Cytochrome P450)
9.	ruxolitinib
10.	avatrombopag